Evidence map›Paper›PMID 30622341›Full record

ArticleOncogene2019

Correction: Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death.

Charlotte E Johnson, Elaine A Dunlop, Sara Seifan, Henry D McCann, Trevor Hay, Geraint J Parfitt, Ashley T Jones, Peter J Giles, Ming H Shen, Julian R Sampson and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Charlotte E JohnsonDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Elaine A DunlopDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Sara SeifanDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Henry D McCannDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Trevor HayEuropean Cancer Stem Cell Research Institute, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK.
Geraint J ParfittEuropean Cancer Stem Cell Research Institute, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK.ORCID http://orcid.org/0000-0002-8704-7906
Ashley T JonesDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Peter J GilesDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Ming H ShenDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Julian R SampsonDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Rachel J ErringtonDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
D Mark DaviesDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Andrew R TeeDivision of Cancer and Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK. teea@cardiff.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article was originally published under standard licence, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly.

Identifiers

PMID30622341
PMCPMC8075855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.